Introduction: Optimal uterine relaxation is achieved through higher minimum alveolar concentration (MAC) of inhalational anesthetics, increasing risks to mother and fetus. Our objective was to determine if earlier administration of magnesium sulfate would reduce the requirement of inhalational anesthetics in fetal myelomeningocele repair. Materials and Methods: Prospective observational study of fetal myelomeningocele repair was performed from September 2011 to August 2017. Groups compared were: (1) magnesium sulfate at uterine closure; (2) magnesium sulfate at maternal skin incision. Maternal demographics, anesthetic agents, intraoperative complications, and pregnancy outcomes were reviewed. A Student t test was used for analysis. Results: There were 30 cases in group 1 and 21 cases in group 2. There was no difference in gestational age at intervention (24.92 ± 0.62 vs. 25.22 ± 0.47 weeks, p = 0.07) or at delivery (34.83 ± 2.77 vs. 33.98 ± 3.83 weeks, p = 0.38) between groups 1 and 2, respectively. The maximum MAC of sevoflurane was significantly lower in group 2 (1.84 ± 0.25 vs. 1.05 ± 0.28, p < 0.0001). There was no difference in the average dose of phenylephrine used. Discussion: Magnesium sulfate infusion initiated earlier in open fetal surgery reduces the total anesthetic exposure to the fetus.

Keywords:
Magnesium sulfate, Inhalational anesthetics, Sevoflurane, Myelomeningocele
1.
Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, Devine O, Petrini J, Ramadhani TA, Hobbs CA, Kirby R: National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999–2001. Birth Defects Res Part A Clin Mol Teratol 2006; 76: 747–756.
2.
Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, Howell LJ, Farrell JA, Dabrowiak ME, Sutton LN, Gupta N, Tulipan NB, D’Alton ME, Farmer DL: A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 2011; 364: 993–1004.
3.
Olutoye OA, Sheikh F, Zamora IJ, Yu L, Akinkuotu AC, Adesina AM, Olutoye OO: Repeated isoflurane exposure and neuroapoptosis in the midgestation fetal sheep brain. Am J Obstet Gynecol 2016; 214: 542.e1–542.e8.
4.
Creeley CE, Dikranian KT, Dissen GA, Back SA, Olney JW, Brambrink AM: Isoflurane-induced apoptosis of neurons and oligodendrocytes in the fetal rhesus macaque brain. Anesthesiology 2014; 120: 626–638.
5.
Ferschl M, Ball R, Lee H, Rollins MD: Anesthesia for in utero repair of myelomeningocele. Anesthesiology 2013; 118: 1211–1223.
6.
US Food and Drug Administration: FDA Drug Safety Communication: FDA Review Results in New Warnings about Using General Anesthetics and Sedation Drugs in Young Children and Pregnant Women. Silver Spring, FDA, 2017.
7.
Response to the FDA. Med Watch December 16, 2016. http://bit.ly/2kA6GEQ.
8.
Thompson SW, Moscicki JC, DiFazio CA: The anesthetic contribution of magnesium sulfate and ritodrine hydrochloride in rats. Anesth Analg 1988; 67: 31–34.
9.
Kafali H, Kaya T, Gursoy S, Bagcivan I, Karadas B, Sarioglu Y: The role of K(+) channels on the inhibitor effect of sevoflurane in pregnant rat myometrium. Anesth Analg 2002; 94: 174–178.
10.
Mercer BM, Merlino AA: Magnesium sulfate for preterm labor and preterm birth. Obstet Gynecol 2009; 114: 650–668.
11.
Palahniuk RJ, Shnider SM: Maternal and fetal cardiovascular and acid-base changes during halothane and isoflurane anesthesia in the pregnant ewe. Anesthesiology 1974; 41: 462–471.
12.
Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF: Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 2003; 23: 876–882.
13.
Brambrink AM, Evers AS, Avidan MS, Farber NB, Smith DJ, Zhang X, Dissen GA, Creeley CE, Olney JW: Isoflurane-induced neuroapoptosis in the neonatal rhesus macaque brain. Anesthesiology 2010; 112: 834–841.
14.
Zhang DX, Jiang S, Yu LN, Zhang FJ, Zhuang Q, Yan M: The effect of sevoflurane on the cognitive function of rats and its association with the inhibition of synaptic transmission. Int J Clin Exp Med 2015; 8: 20853–20860.
15.
Suehara T, Morishita J, Ueki M, Ueno M, Maekawa N, Mizobuchi S: Effects of sevoflurane exposure during late pregnancy on brain development of offspring mice. Paediatr Anaesth 2016; 26: 52–59.
16.
Crowther CA, Hiller JE, Doyle LW, Haslam RR: Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669–2676.
17.
Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, Bénichou J: Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007; 114: 310–318.
18.
Marret S, Marpeau L, Follet-Bouhamed C, Cambonie G, Astruc D, Delaporte B, Bruel H, Guillois B, Pinquier D, Zupan-Simunek V, Bénichou J: Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial (in French). Gynecol Obstet Fertil 2008; 36: 278–288.
19.
Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp JM Jr, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O’Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM: A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359: 895–905.
20.
Costantine MM, Weiner SJ: Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants. Obstet Gynecol 2009; 114: 354–364.
21.
Simhan HN: Practice bulletin No. 171: management of preterm labor. Obstet Gynecol 2016; 128:e155–e164.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.